An observational study in Breast Carcinoma, sponsored by Basavatarakam Indo American Cancer Hospital & Research Institute. Recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Basavatarakam Indo American Cancer Hospital & Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Breast Neoplasms with a site in India — 20 open to participants now, 53 under way, 37 of them phase 3. Breast Neoplasms · India.
Among the 182 studies in Breast Neoplasms with a site in India, this one is the 5th largest by planned enrollment of the 19 observational ones that give a count, is one of 13 that started in 2025, is one of 19 observational ones, reaches primary completion later than 14 of the 52 other live ones, and was the 175th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →20 of the 182 studies in Breast Neoplasms with a site in India are open now. Recruiting first, the newest first:
Natureceuticals Sdn Bhd · Sites in India
Ages 18–65 · Women only
Bristol-Myers Squibb · Sites in India, United States, Argentina and 25 more countries
Ages 18+
All India Institute of Medical Sciences, Bhubaneswar · Sites in India
Ages 18–75 · Women only
Pfizer · Sites in India, United States, Argentina and 28 more countries
Ages 18–99
Merck Sharp & Dohme LLC · Sites in India, United States, Argentina and 38 more countries
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 44 · Phase 3 86 · Phase 4 11
First in 1997; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 333 across the 161 interventional studies, 595 across the 19 observational. Of the 116 that completed or were terminated, 70 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 182 have an industry lead sponsor. The 10 most frequent:
Basavatarakam Indo American Cancer Hospital & Research Institute is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Basavatarakam Indo American Cancer Hospital & Research Institute has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
15 of the studies in Breast Neoplasms with a site in India that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05894239Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | 2027-05-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 182 studies in Breast Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine the proportion of patients who are lost-to-follow-up at five years, identify factors associated with loss of follow-up , and explore patient-reported barriers to follow-up in a public sector cancer care setting.
The main question it aims to answer is : Do proactive outreach programs help in improving follow-up rates among breast cancer patients who are categorized as "lost-to-follow-up." This study will be conducted in a real-world cohort of women with non-metastatic breast cancer treated at a tertiary care centre, between 2017-2018.
This is a prospective cohort study involving women diagnosed with non-metastatic breast cancer in the years 2017-2018, who received treatment at our institute. Baseline data collection will include essential demographic information, clinical data including tumor characteristics, stage at presentation and luminal subtype and treatment information including surgical intervention, chemotherapy, radiotherapy, hormonal therapy, and targeted therapy.
The study will be conducted in three phases.
This is a prospective cohort study involving women diagnosed with non-metastatic breast cancer in the years 2017-2018, who received treatment at our institute, Basavatarakam Indo American Cancer Hospital \& Research Institute, Hyderabad, India.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal Criteria:
1. Patient withdraws consent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All women with newly diagnosed non-metastatic breast cancer, presenting to Basavatarakam Indo American Cancer Hospital \& Research Institute, Hyderabad, India, between 2017 - 2018 will be included in the study. The analysis will focus on the women who have been lost-to-follow-up.
Improvement in follow-up data with proactive outreach
Follow-up data will be retrieved from hospital records and electronic medical records (EMR) up to December 2024. For patients identified as lost-to-follow-up, proactive outreach efforts will be undertaken via phone calls, messages, or emails. Patients (or their families) will be queried about recurrence of disease, and these responses will be documented as valid follow-up entries.
Time frame: 6 months
Updated mortality data
For patients identified as lost-to-follow-up, proactive outreach efforts will be undertaken via phone calls, messages, or emails. Patients (or their families) will be queried about mortality (if applicable) and these responses will be documented as valid follow-up entries.
Time frame: 6 months
3. Evaluate the reasons for patient disengagement from follow-up care.
During outreach, participants will also be asked to identify reasons for missing follow-up visits. These will be documented as qualitative entries.
Time frame: 6 months
Assessment of willingness for future hospital contact
Participants will be asked about their willingness to maintain hospital contact in the future and their preferred mode of communication.
Time frame: 6 months
Plan to share: Undecided — Since this study involves contacting women who are lost-to-follow-up, the investigators are considering various options for sharing IPD, with appropriate consent from the participants.
Started May 2025 (actual). Primary completion is estimated for Sep 2025, 4 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 4 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Basavatarakam Indo American Cancer Hospital & Research Institute